Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | SYK | P43405 | 1/20 | 0.57 |
| ▸ | CTSK | P43235 | 5/20 | 0.53 |
| ▸ | KLK7 | P49862 | 2/20 | 0.52 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | TGM2 | P21980 | 1/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL699601 | 1.00 | MAPT (0.61) | MAPTSYKCTSKKLK7KLK5 | |
| SCHEMBL5500108 | 0.97 | SYK (0.58) | MAPTSYKCTSKKLK7KLK5 | |
| SCHEMBL4821212 | 0.96 | MAPT (0.66) | MAPTSYKCTSKKLK7KLK5 | |
| SCHEMBL4179699 | 0.93 | MAPT (0.62) | MAPTSYKCTSKKLK7KLK5 | |
| SCHEMBL24152311 | 0.90 | FOLH1 (0.58) | CTSKFOLH1TGM2 | |
| SCHEMBL8607096 | 0.90 | FOLH1 (0.58) | CTSKFOLH1TGM2 | |
| SCHEMBL24845372 | 0.86 | MAPT (0.64) | MAPTSYKKLK7KLK5L3MBTL1 | |
| SCHEMBL23453055 | 0.85 | CTSK (0.54) | MAPTSYKCTSKKLK7KLK5 | |
| SCHEMBL15670737 | 0.85 | CTSK (0.53) | MAPTSYKCTSKCTSLCTSB | |
| SCHEMBL15670736 | 0.85 | CTSK (0.53) | MAPTSYKCTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059231-A1 | Protease inhibitors | PROTINHI B.V. (NL) | 2025-02-20 | — | — | US | disclosed |
| WO-2024200819-A1 | PROTEASE INHIBITORS FOR CORONAVIRAL INFECTIONS | PROTINHI B.V. (NL) | 2024-10-03 | — | — | WO | disclosed |
| EP-4408454-A1 | PROTEASE INHIBITORS | Protinhi B.V. (NL) | 2024-08-07 | — | — | EP | disclosed |
| US-11691997-B2 | Macrocycles | LUMIPHORE, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| WO-2023052636-A1 | PROTEASE INHIBITORS | PROTINHI B.V. (NL) | 2023-04-06 | — | — | WO | disclosed |
| US-11332464-B2 | Inhibitors of lysine gingipain | Cortexyme, Inc. (US) | 2022-05-17 | — | — | US | disclosed |
| US-20210017167-A1 | INHIBITORS OF LYSINE GINGIPAIN | Cortexyme, Inc. (US) | 2021-01-21 | — | — | US | disclosed |
| EP-3204352-B1 | INHIBITORS OF LYSINE GINGIPAIN | CORTEXYME INC (US) | 2020-07-01 | — | — | EP | disclosed |
| CN-111349053-A | Inhibitors of lysine porphyromonas gingivalis protease | 库特克希米公司 | 2020-06-30 | — | — | CN | disclosed |
| US-10676470-B2 | Inhibitors of lysine gingipain | Cortexyme, Inc. (US) | 2020-06-09 | — | — | US | disclosed |
| US-7951823-B2 | Compounds and compositions as channel activating protease inhibitors | IRM LLC (BM) | 2011-05-31 | — | — | US | disclosed |
| US-7939547-B2 | Compounds and compositions as channel activating protease inhibitors | IRM LLC (BM) | 2011-05-10 | — | — | US | disclosed |
| US-7939547-B2 | Compounds and compositions as channel activating protease inhibitors | IRM LLC (BM) | 2011-05-10 | — | — | US | disclosed |
| US-20100056756-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2010-03-04 | — | — | US | disclosed |
| US-20100056756-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2010-03-04 | — | — | US | disclosed |
| WO-2007140117-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2007-12-06 | — | — | WO | disclosed |
| US-20070276002-A1 | Compounds and Compositions as Channel Activating Protease Inhibitors | IRM LLC (BM) | 2007-11-29 | — | — | US | disclosed |
| US-20070276002-A1 | Compounds and Compositions as Channel Activating Protease Inhibitors | IRM LLC (BM) | 2007-11-29 | — | — | US | disclosed |
| US-20070275906-A1 | Compounds and Compositions as Channel Activating Protease Inhibitors | IRM LLC (BM) | 2007-11-29 | — | — | US | disclosed |
| US-20070275906-A1 | Compounds and Compositions as Channel Activating Protease Inhibitors | IRM LLC (BM) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017167-A1 | INHIBITORS OF LYSINE GINGIPAIN | ENPEP, PHYKPL, PREP | MAPT 332/4885SYK 900/4885CTSK 631/4885 |
| US-11691997-B2 | Macrocycles | HCCS, ABCB7, AURKAIP1 | MAPT 1131/4885SYK 3235/4885CTSK 486/4885 |
| US-10676470-B2 | Inhibitors of lysine gingipain | ENPEP, PHYKPL, PREP | MAPT 332/4885SYK 900/4885CTSK 631/4885 |
| US-20100056756-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | PRSS1, PRSS8, PRSS2 | MAPT 1916/4885SYK 4691/4885CTSK 40/4885 |
| US-20070276002-A1 | Compounds and Compositions as Channel Activating Protease Inhibitors | PRSS1, PRSS8, PRSS2 | MAPT 1869/4885SYK 4712/4885CTSK 40/4885 |
| US-20250059231-A1 | Protease inhibitors | PREP, DNPEP, TMPRSS15 | MAPT 1231/4885SYK 4506/4885CTSK 165/4885 |
| US-11332464-B2 | Inhibitors of lysine gingipain | ENPEP, PHYKPL, PREP | MAPT 332/4885SYK 900/4885CTSK 631/4885 |
| US-20070275906-A1 | Compounds and Compositions as Channel Activating Protease Inhibitors | PRSS1, PRSS8, PRSS2 | MAPT 1916/4885SYK 4691/4885CTSK 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.